New pill shows promise for Hard-to-Treat leukemia and lymphoma
NCT ID NCT04849416
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check for side effects. Participation lasted up to four years. Results showed that some participants responded to the drug, offering hope for those who have run out of options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pirtobrutinib (also called LOXO-305), an oral targeted therapy
- What this could lead to
- If successful, this could offer a new treatment option for people with certain blood cancers who have stopped responding to other therapies.
- What could go wrong
- This is a phase 2 study with a small number of participants (87) and no comparison group. Results may not apply to all patients, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Hebei University
Baoding, Hebei, 71066, China
-
Beijing Cancer hospital
Beijing, Beijing Municipality, 100142, China
-
Hainan General Hospital
Haikou, Hainan, 570311, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Institute of hematology&blood disease hospital
Tianjin, Tianjin Municipality, 300020, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210000, China
-
Shanghai East Hospital
Shanghai, 200120, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 610041, China
-
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, 510515, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 511400, China
-
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, Henan, 471003, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215066, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Wannan Medical College Yijishan Hospital
Wuhu, Anhui, 241001, China
-
Xi'an International Medical Center Hospital
Xi'an, Shaanxi, 710126, China
-
Xiangya Hospital Central South University
Changsha, Hunan, 410008, China
-
Xingtai People's Hospital
Xingtai, Hebei, 054031, China
-
Xinjiang Medical University Cancer Hospital - Urumqi
Ürümqi, Xinjiang, 830000, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can a single shot build a cancer army inside the body?
- Personalized chemo and transplants aim to beat infant leukemia
- Rare childhood bone lymphoma: can past cases guide future care?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- CAR-T breakthroughs come with infection risks – new study aims to decode them